Gemphire Therapeutics’ Clinically Demonstrated Gemcabene Medication

As the head of capital markets and the managing partner at Laidlaw & Company in New York, James Ahern focuses on an expanding healthcare investment market. James (Jim) Ahern and the Laidlaw team have successfully engineered initial public offerings for Therapix Biosciences, Cerecor, and Gemphire Therapeutics, among others. 

Gemphire, a Michigan-based clinical-stage biopharmaceutical enterprise, focuses on the commercialization of treatments for patients living with nonalcoholic steatohepatitis, dyslipidemia, and cardiometabolic disorders. Gemcabene, licensed from Pfizer in 2011, is a promising oral drug candidate that effectively decreases inflammation, LDL-C, and fat in the form of triglycerides. 

To date, nearly 200 clinical gemcabene Phase 1 and Phase 2 trials have been accomplished, both as a monotherapy and in tandem with statins of various dosages. The market size for this drug, which has been demonstrated as safe and effective, is estimated at 20 million patients and $33 billion by 2025.